The contribution of positron emission tomography to the study of ischemic heart failure

Progress in Cardiovascular Diseases

Volumn 43, Issue 5, 2001, Pages 399-418

  Dutka, David P ^a   Camici, Paolo G ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DIAGNOSTIC IMAGING; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE METABOLISM; HEART MUSCLE REVASCULARIZATION; INFORMATION PROCESSING; ISCHEMIC HEART DISEASE; MYOCARDIAL HIBERNATION; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 0035103389     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1053/pcad.2001.20673     Document Type: Article

References (105)

1. The imaging science of positron emission tomography
2. The impact of myocardial blood flow quantitation with PET on the understanding of cardiac diseases
3. Pathophysiological mechanisms of chronic reversible left ventricular dysfunction due to coronary artery disease (hibernating myocardium)
4. Attenuation correction in PET using single photon transmission measurement
5. Model-based scatter correction for fully 3D PET
6. Non-rigid summing of gated PET via optical flow
7. Principles of positron emission tomography
8. Requisites to modelling of tracer kinetics in the heart using positron emission tomography
9. Methodological issues in regional myocardial perfusion imaging with positron emission tomography
10. Physical performance of the latest generation of commercial positron scanners
11. Maximum likelihood reconstruction for emission tomography
12. PET Studies of the heart
13. Quantification in positron emission tomography
14. Cardiac emission computed tomography: Underestimation of regional tracer concentrations due to wall motion abnormalities
15. Myocardial tissue fraction: Correction for partial volume effects and measure of tissue viability
16. Regional oxidative metabolism in patients after recovery from reperfused anterior myocardial infarction
17. Non invasive quantification of regional myocardial blood flow in coronary artery disease with oxygen-15 labeled carbon dioxide inhalation and positron emission tomography
18. Noninvasive quantification of myocardial blood flow in human subjects with O-15 labelled water and positron emission tomography
19. 15O-water estimates of perfusion with quantification of regional myocardial blood flow by microspheres
20. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomography
21. 15O and dynamic positron emission tomography
22. N-13 ammonia myocardial imaging at rest and with exercise in normal volunteers. Quantification of absolute myocardial perfusion with dynamic positron emission tomography
23. N-13 ammonia as an indicator of myocardial blood flow. Factors influencing its uptake and retention in myocardium
24. 13N-ammonia as an indicator of myocardial blood flow
25. Heterogeneity of myocardial perfusion provides the physiological basis of "perfusable tissue index"
26. 15O]water techniques
27. 15O-water and dynamic positron emission tomography
28. The role of positron emission tomography in the investigation of coronary circulatory function in man
29. Profound spatial heterogeneity of coronary reserve. Discordance between patterns of resting and maximal myocardial blood flow
30. Spatial heterogeneity of myocardial blood flow presages salvage vs necrosis with coronary artery reperfusion in conscious baboons
31. Quantitative myocardial mapping of perfusion and metabolism using parametric polar map display in cardiac PET
32. Variability of myocardial blood flow measured by positron emission tomography and oxygen-15-labeled water in 153 volunteers
33. 15O-labelled water and PET
34. Transmural myocardial blood flow distribution in hypertrophic cardiomyopathy and effect of treatment
35. Myocardial blood flow as a function of coronary stenosis severity in man
36. Mechanisms of chronic regional postischemic dysfunction in humans. New insights from the study of noninfarcted collateral-dependent myocardium
37. Delayed recovery of coronary resistive function after coronary angioplasty
38. Persistent but reversible coronary microvascular dysfunction after bypass grafting
39. Altered coronary vasodilator reserve and metabolism in myocardium subtended by normal coronary arteries in patients with coronary artery disease
40. Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography
41. Beneficial effects of cardiovascular conditioning on myocardial blood flow and coronary vasodilator capacity
42. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population
43. Postextrasystolic potentiation of ischemic myocardium by atrial stimulation
44. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina
45. The hibernating myocardium
46. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography
47. Delineation of myocardial viability with PET
48. Correlation between acute reductions in myocardial blood flow and function in conscious dogs
49. Effect of exercise on the relationship between MBF and systolic wall thickening in dogs with acute coronary stenosis
50. Regional myocardial perfusion and wall thickening during ischaemia in conscious dogs
51. Effects of dobutamine stimulation on myocardial blood flow, glucose metabolism, and wall motion in normal and dysfunctional myocardium
52. Myocardial metabolism in ischemic heart disease: Basic principles and application to imaging by positron emission tomography
53. Coronary haemodynamics and myocardial metabolism during and after pacing stress in normal humans
54. C-11 palmitic acid for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron computed tomography. IV: In vivo demonstration of impaired fatty acid oxidation in acute myocardial ischaemia
55. Noninvasive estimation of regional myocardial oxygen consumption by positron emission tomography with carbon-11 acetate in patients with myocardial infarction
56. 11C]acetate and dynamic positron emission tomography
57. 2 inhalation and positron emission tomography
58. 18F] 2-deoxy-2-fluoro-D-glucose
59. 18F]fluorodeoxyglucose
60. Metabolic and hemodynamic effects of insulin on human hearts
61. Essential hypertension, metabolic disorders, and insulin resistance
62. Hyperinsulinemia as an independent risk factor for ischemic heart disease
63. Insulin resistance, compensatory hyperinsulinaemia, and coronary heart disease
64. Mechanism of insulin resistance in insulin-dependent diabetes mellitus: A major role for reduced skeletal muscle blood flow
65. Enhanced sympathetic nervous system activity. The linchpin between insulin resistance, hyperinsulinemia, and heart rate
66. Left ventricular remodeling in myocardial hibernation
67. Hibernating myocardium
68. Endsystolic volume and long-term survival after coronary artery bypass graft surgery in patients with impaired left ventricular function
69. The hibernating myocardium: Implications for management of congestive heart failure
70. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography
71. Predictive value of dobutamine echocardiography and positron emission tomography in identifying hibernating myocardium in patients with postischaemic heart failure
72. Failure to improve left ventricular function after coronary revascularisation for ischaemic cardiomyopathy is not associated with a worse outcome
73. Myocardial blood flow, glucose uptake, and recruitment of inotropic reserve in chronic left ventricular ischemic dysfunction. Implications for the pathophysiology of chronic myocardial hibernation
74. Coronary artery bypass surgery as treatment for ischemic heart failure: The predictive value of viability assessment with quantitative positron emission tomography for symptomatic and functional outcome
75. Relation of regional function, perfusion, and metabolism in patients with advanced coronary artery disease undergoing surgical revascularization
76. Revascularization for post-ischaemic heart failure: How myocardial viability affects survival
77. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability
78. Myocardial viability assessment in ischemic cardiomyopathy: Benefits of coronary revascularization
79. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy
80. Identification of viable myocardium
81. Coronary revascularization in the treatment of moderate and severe postischemic left ventricular dysfunction
82. Regional perfusion, glucose metabolism, and wall motion in patients with chronic electrocardiographic Q wave infarctions: Evidence for persistence of viable tissue in some infarct regions by positron emission tomography
83. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic cotonary artery disease: Comparison of pooled data
84. Stress echocardiography: Recommendations for performance and interpretation of stress echocardiography
85. Glucose clamp technique: A method for quantifying insulin secretion and resistance
86. Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography
87. Insulin resistance in patients with cardiac hypertrophy
88. Pathophysiology of chronic left ventricular dysfunction. New insights from the measurement of absolute myocardial blood flow and glucose utilization
89. Efficacy of coronary angioplasty for the treatment of hibernating myocardium
90. Prognostic value of the amount of dysfunctional but viable myocardium in revascularized patients with coronary artery disease and left ventricular dysfunction
91. Assessment of myocardial viability in patients with chronic coronary artery disease. Rest-4-hour-24-hour 201TI tomography versus dobutamine echocardiography
92. Increased sarcolemmal glucose transporter abundance in myocardial ischemia
93. Structural and metabolic correlates of the reversibility of chronic left ventricular ischemic dysfunction in humans
94. Histological alterations in chronically hypoperfused myocardium. Correlation with PET findings
95. Positron emission tomography: Evaluation of cardiac receptors
96. Diffuse reduction of myocardial beta-adrenoceptors in hypertrophic cardiomyopathy: A study with positron emission tomography
97. Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy
98. Positron emission tomography with 11C CGP-12177 to assess beta-adrenergic receptor concentration in idiopathic dilated cardiomyopathy
99. Myocardial beta adrenoceptors and left ventricular function in hypertrophic cardiomyopathy
100. 1-adrenoceptors with positron emission tomography
101. Neuronal mapping of the heart with 6-[F-18]-Fluorometaeaminol
102. Positron emission tomographic imaging of cardiac sympathetic innervation and function
103. Noninvasive evaluation of the sympathetic nervous system in the human heart by PET
104. Chest pain in cardiac-transplant recipients. Evidence for sensory reinnervation after cardiac transplantation
105. Cardiac sympathetic innervation in patients with idiopathic right ventricular outflow tract tachycardia